2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
about
Emerging Tools for Stroke Prevention in Atrial FibrillationChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewMinimizing bleeding risk in patients receiving direct oral anticoagulants for stroke preventionPercutaneous left atrial appendage closure devices: safety, efficacy, and clinical utilitySubclinical atrial fibrillation and stroke: insights from continuous monitoring by implanted cardiac electronic devicesEpidemiology, diagnosis, and management of atrial fibrillation in womenCardioembolic Stroke.New-Onset Atrial Fibrillation in the Critically IllImproving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial.Insertable cardiac monitors in the diagnosis of syncope and the detection of atrial fibrillation: A systematic review and meta-analysis.Sex differences in management and outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events (Gulf SAFE).Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.Managing atrial fibrillation.Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis.Amiodarone use is associated with increased risk of stroke in patients with nonvalvular atrial fibrillation: a nationwide population-based cohort study.Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants.Anticoagulation and population risk of stroke and death in incident atrial fibrillation: a population-based cohort study.The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies.CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation.Individualising Anticoagulant Therapy in Atrial Fibrillation PatientsPresence of diabetic microvascular complications does not incrementally increase risk of ischemic stroke in diabetic patients with atrial fibrillation: A nationwide cohort study.Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.Which Factors Influence Resident Physicians to Prescribe NOACs to Patients with Non-Valvular Atrial Fibrillation?Short-Term Risk of Bleeding During Heparin Bridging at Initiation of Vitamin K Antagonist Therapy in More Than 90 000 Patients With Nonvalvular Atrial Fibrillation Managed in Outpatient CareAppropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study.Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation.Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.Implications for your practice: Important changes in the 2014 guideline for the management of patients with atrial fibrillation.Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.Rate-control with beta-blockers versus calcium-channel blockers in the emergency setting: predictors of medication class choice and associated hospitalization.Prognostic factors of clinical endpoints in elderly patients with atrial fibrillation during a 2-year follow-up in China: An observational cohort study.Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment.Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?Between- and within-site variation in medication choices and adverse events during procedural sedation for electrical cardioversion of atrial fibrillation and flutter.Asymptomatic atrial fibrillation burden and thromboembolic events: piecing evidence together.Clinical implications of reversal agents for direct oral anticoagulants.Atrial fibrillation management: evaluating rate vs rhythm control.Catheter Ablation as First-Line Therapy for Atrial Fibrillation: Ready for Prime-Time?
P2860
Q26765023-77015C79-AF66-488D-B6EC-0C521FA20E6FQ26765949-D0EBEA60-D234-4139-97D9-F7F55F151128Q28069809-FD67E15C-3F20-4B10-AAA4-F51F85DE1341Q28071688-A5CA8E7D-B79F-455E-925D-A6BEE2618E98Q28074643-A0923219-7F3D-436C-BECB-18D4A4742561Q28083655-368E8072-8C83-415F-B1EC-81FAE343DB2FQ30238631-DA73FBED-46BF-4305-9394-4408E824E350Q30252948-34423528-FF0A-40FA-8402-65B1FEC0E64CQ30830699-AEC74DF0-04C4-457A-8C20-68770856B42CQ33166805-A1A00E4C-00E5-4D0A-9ACF-8272F484DF2BQ33698854-6AA7C515-69C4-4B0D-B988-59D3C7624BABQ35868819-544F24DF-E018-4A5D-8E48-9EEA7639C016Q35900515-97DF6483-BD82-4EEA-B750-6D13DEEE7421Q36069462-87C3EF34-78BB-4B74-B925-61C4899E8BD4Q36151596-4B94C33C-C874-4BB4-969E-2F55D1CE894FQ36874702-F9CF49B3-905D-4FF2-8665-1D511B87560CQ36900966-E5805703-6216-478C-9EF8-B80E2BC65D4DQ37030683-5E0ADB0A-E1A9-4B5E-94F5-0463E017C219Q37109098-A355E0D3-EB51-4999-811A-308ED3B9FE23Q37235927-46BBEB68-DA5D-4BC9-BA16-D9E2F4AAE3E3Q37327914-F438E50A-F22F-4222-9EC4-2433C4A8B668Q37376804-22A59FB1-6DD2-41AF-B0B1-C03B8952C59CQ37456963-F29A0C22-6BB8-4851-BAF7-93C61CB64323Q37556151-FB113EF3-5C2F-44F4-BA3C-58DD7C959071Q37591967-FEF586A0-A92E-4F46-A485-C55FCBF4B12DQ37627206-0D5D2E54-997B-41B2-93C5-A8B7216E50E0Q37672517-3A66BD56-48CC-45E5-BB30-1767FBE208E4Q38303442-0CFD34E7-6234-4174-AD75-039A7A3D1E29Q38386998-37D01659-0376-46E6-854A-ECDA98894B46Q38392143-D85DB793-883F-448A-86D7-590A69053BA8Q38529659-9A27369F-C397-4FF6-909F-6D06041DF55CQ38602512-E918B671-6071-4FC6-9843-BBF5FBF82E4FQ38620315-EA376C65-045C-4083-B9AE-F33BF466D28FQ38708508-6B9E7357-9759-4C6E-90F0-9E175D312A5CQ38728028-9DB65F9F-4A4D-4C32-956B-B6087920CBE4Q38740051-CB9C848F-B706-42F0-BF58-3BF95E89A2D6Q38740626-88A7D92E-F634-4339-AC6E-DB8296506AC1Q38757405-2E85F3CF-DC85-4297-A50B-ED16B3B8E93DQ38767173-BA4CD435-831C-45F1-9480-279671117000Q38864989-14DC610F-F303-4F68-8391-6CA1ED95AB91
P2860
2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
2014 focused update of the Can ...... gement of atrial fibrillation.
@en
2014 focused update of the Can ...... gement of atrial fibrillation.
@nl
type
label
2014 focused update of the Can ...... gement of atrial fibrillation.
@en
2014 focused update of the Can ...... gement of atrial fibrillation.
@nl
prefLabel
2014 focused update of the Can ...... gement of atrial fibrillation.
@en
2014 focused update of the Can ...... gement of atrial fibrillation.
@nl
P2093
P50
P1476
2014 focused update of the Can ...... gement of atrial fibrillation.
@en
P2093
Atul Verma
CCS Atrial Fibrillation Guidelines Committee
Jafna L Cox
Jeff S Healey
John A Cairns
Kori Leblanc
L Brent Mitchell
Laurent Macle
Michael Sean McMurtry
Noah Ivers
P304
P356
10.1016/J.CJCA.2014.08.001
P577
2014-08-13T00:00:00Z